deferiprone has been researched along with malondialdehyde in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdallah, MA; Brissot, P; Cillard, J; Cillard, P; Lescoat, G; Morel, I; Ocaktan, AZ; Pasdeloup, N; Sergent, O | 1 |
| Caisová, D; Eybl, V; Kontoghiorghes, GJ; Koutenský, J | 1 |
| Brissot, P; Chenoufi, N; Cillard, J; Hubert, N; Lescoat, G; Loréal, O; Morel, I; Pasdeloup, N | 1 |
| Abrahamov, A; Goldfarb, A; Grinberg, L; Hebbel, RP; Olivieri, NF; Rachmilewitz, EA; Repka, T; Shalev, O | 1 |
| Brittenham, G; Lin, M; Niemelä, O; Rippe, RA; Tsukamoto, H | 1 |
| Jin, L; Li, PP; Lu, WY; Pan, H; Wei, G; Xu, LJ; Zhang, AZ | 1 |
| Fucharoen, S; Mundee, Y; Ounjaijean, S; Pattanapanyasat, K; Porter, JB; Saewong, T; Srichairatanakool, S | 1 |
| Ammar, el-SM; El-Damarawy, SL; Said, SA; Suddek, GM | 1 |
| Bao, Y; Li, S; Liu, X; M, S; Sui, M; Xie, R; Yin, H; Zou, C | 1 |
| Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S | 1 |
| Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Khamseekaew, J; Kumfu, S; Srichairatanakool, S; Sripetchwandee, J; Wongjaikam, S | 1 |
| Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Jaiwongkam, T; Kerdphoo, S; Khamseekaew, J; Kumfu, S; Srichairatanakool, S; Wongjaikam, S | 1 |
| Abnous, K; Etemad, L; Imenshahidi, M; Karimi, G; Makhdoumi, P; Mehri, S | 1 |
1 trial(s) available for deferiprone and malondialdehyde
| Article | Year |
|---|---|
Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Deferiprone; Erythrocyte Membrane; Erythrocytes; Humans; Iron; Iron Chelating Agents; Lipid Peroxidation; Malondialdehyde; Pyridones; Splenectomy; Thiobarbituric Acid Reactive Substances | 1995 |
12 other study(ies) available for deferiprone and malondialdehyde
| Article | Year |
|---|---|
Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.
Topics: Animals; Antioxidants; Calcium-Binding Proteins; Cells, Cultured; Chromatography, High Pressure Liquid; Cyclic N-Oxides; Deferiprone; Deferoxamine; Ethanol; Free Radical Scavengers; Free Radicals; Hydroxides; Hydroxyl Radical; Iron; Iron Chelating Agents; Kinetics; Lipid Peroxidation; Liver; Malondialdehyde; Oligopeptides; Photolysis; Pigments, Biological; Pyridones; Rats; Rats, Sprague-Dawley | 1992 |
Influence of iron chelators, 1,2-dialkyl-3-hydroxypyridin-4-ones, on the lipid peroxidation and glutathione level in the liver of mice.
Topics: Animals; Cadmium; Carbon Tetrachloride; Deferiprone; Glutathione; In Vitro Techniques; Indium; Iron; Iron Chelating Agents; Lipid Peroxidation; Liver; Male; Malondialdehyde; Mice; Mice, Inbred ICR; Pyridones | 1991 |
Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Cells, Cultured; Deferiprone; Extracellular Space; Humans; Iron; Iron Chelating Agents; Iron Radioisotopes; L-Lactate Dehydrogenase; Liver; Male; Malondialdehyde; Microscopy, Electron; Pyridones; Rats; Rats, Sprague-Dawley | 1995 |
Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages.
Topics: Animals; Cholestasis; Common Bile Duct; Cytokines; Deferiprone; Interleukin-6; Iron; Iron Chelating Agents; Kupffer Cells; Liver; Male; Malondialdehyde; NF-kappa B; Pyridones; Rats; Rats, Wistar; RNA, Messenger; Thiobarbituric Acid Reactive Substances; Time Factors; Transcription, Genetic; Tumor Necrosis Factor-alpha | 1997 |
Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin.
Topics: Animals; Deferiprone; Doxorubicin; Heart Atria; Iron Chelating Agents; Male; Malondialdehyde; Mitochondria; Mitochondrial Swelling; Myocardial Contraction; Pyridones; Random Allocation; Rats; Rats, Sprague-Dawley; Succinate Dehydrogenase; Superoxide Dismutase | 2006 |
Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice.
Topics: Administration, Oral; Animals; beta-Thalassemia; Collagen; Deferiprone; Dietary Supplements; Ferrous Compounds; Glutathione; Iron; Iron Overload; Liver; Male; Malondialdehyde; Metallocenes; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Plant Extracts; Pyridones; Tea | 2010 |
Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats.
Topics: Aconitine; Animals; Antibiotics, Antineoplastic; Creatine Kinase, MB Form; Deferiprone; Doxorubicin; Drug Interactions; Electrocardiography; Glutathione; Heart; Heart Diseases; Heart Rate; Iron; Iron Chelating Agents; L-Lactate Dehydrogenase; Male; Malondialdehyde; Myocardium; Pyridones; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Superoxide Dismutase; Tachycardia, Ventricular | 2011 |
Iron chelator alleviates tubulointerstitial fibrosis in diabetic nephropathy rats by inhibiting the expression of tenascinC and other correlation factors.
Topics: Animals; Deferiprone; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Iron Chelating Agents; Kidney; Male; Malondialdehyde; Pyridones; Rats; Rats, Wistar; Superoxide Dismutase; Tenascin | 2013 |
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cardiovascular Diseases; Deferasirox; Deferiprone; Deferoxamine; Dihydropyridines; Heart; Iron Chelating Agents; Iron Overload; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Mitochondria; Nitrophenols; Organophosphorus Compounds; Pyridones; Thalassemia; Triazoles | 2016 |
Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats.
Topics: Acetylcysteine; Animals; Benzoates; Cardiomyopathies; Cardiotonic Agents; Deferasirox; Deferiprone; Deferoxamine; Drug Combinations; Drug Synergism; Humans; Iron; Iron Chelating Agents; Iron Overload; Iron, Dietary; Male; Malondialdehyde; Mitochondria; Pyridones; Rats; Rats, Wistar; Triazoles; Ventricular Function, Left | 2016 |
Effects of iron overload, an iron chelator and a T-Type calcium channel blocker on cardiac mitochondrial biogenesis and mitochondrial dynamics in thalassemic mice.
Topics: Aminophylline; Animals; Apoptosis; Atropine; Blood Pressure; Calcium Channel Blockers; Calcium Channels, T-Type; Deferiprone; Dihydropyridines; Drug Combinations; Heart; Heart Rate; Iron; Iron Chelating Agents; Iron Overload; Male; Malondialdehyde; Mice; Mitochondria; Myocardium; Nitroglycerin; Nitrophenols; Organelle Biogenesis; Organophosphorus Compounds; Oxidative Phosphorylation; Papaverine; Phenobarbital; Pyridones; Signal Transduction; Thalassemia | 2017 |
Oral deferiprone administration ameliorates cisplatin-induced nephrotoxicity in rats.
Topics: Aconitate Hydratase; Administration, Oral; Animals; Blood Urea Nitrogen; Cisplatin; Creatinine; Deferiprone; Dose-Response Relationship, Drug; Hypoxia-Inducible Factor 1, alpha Subunit; Iron; Lipid Peroxidation; Male; Malondialdehyde; Protective Agents; Rats; Receptors, Transferrin; Renal Insufficiency; Superoxide Dismutase | 2018 |